From Neuland Q2 FY24 Investor presentation,
Biotech companies are more aggressive in focusing on small molecules, hence they have a higher approval rate compared to Big Pharma companies, which are continuing to focus on biologics.
I used to assume that the biotech companies focuses more on biologics as they have bio in its name.
If they focuses more on small molecules, why did they have bio in its name?
Subscribe To Our Free Newsletter |